Drugs for Treating Congestive Heart Failure: Global Markets--Focus on the Americas

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objectives of the study are to present a comprehensive look at the drugs for treating congestive heart failure (CHF)—global market measurements of both the overall market and all possible market segments, and to forecast market and segment growth during the next 5 years.

REASONS FOR STUDY

This BCC study will increase the awareness of drugs to treat congestive heart failure.The study analyzes the global market for select drugs for treating the congestive heart failure.It does so from different standpoints and addresses issues and trends affecting the market.Congestive heart failure drug manufacturers, driven by both research breakthroughs and increased recognition of expanding market opportunities, have stepped up the pace of development of innovative products.Because of the evolving nature of this important area of study, executives of product development for congestive heart failure drugs must remain ever vigilant of the changing environment and strive to keep abreast of new and currently used modalities in all facets of the market.

SCOPE OF STUDY

This report is a comprehensive business tool designed to provide an in-depth look at drugs for the congestive heart failure market.The geographic scope of the report is global with a special emphasis on individual regions.The report describes the industry, its relationship to the healthcare industry and its participants, and trends for the future.

Categories discussed in the report include:

• Angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blocker antagonists (ARBs)
• Beta-adrenergic receptor blocking agents
• Diuretics
• Inotropic drugs/vasodilators

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2010 to 2016, and assessing the competitors and competitor market shares.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study.The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary research sources, including executives, product managers, and clinical specialists in the congestive heart failure drug development arena.Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of congestive heart failure.

Key information from published literature was used to conduct interviews with more than 20 industry participants to validate and obtain expert opinions on current and future trends in the congestive heart failure drug market.Interviews were the primary basis for development of market size.Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to the global market at the manufacturer’s level.Data are expressed in current U.S. dollars.The base year was 2011.Historical data are provided for 2010 and forecast data are provided for 2016.Historical, base year, and forecast data are provided for each market segment and subsegment.Market shares are provided for each market segment for the 2011 base year.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 20 years.She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry.Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology, and is currently working on a PhD.

BCC ONLINE SERVICES

BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:

• Examine BCC’s complete catalog of Market Research Reports and place direct orders
• Subscribe to any of BCC’s many industry newsletters
• Read announcements of recently published reports and newly launched newsletters
• Register for BCC’s well-known conferences
• Request additional information on any BCC product
• Take advantage of special offers.

Table Of Contents

Chapter- 1: INTRODUCTION - Complimentary 3

STUDY GOALS AND OBJECTIVES
REASONS FOR STUDY
SCOPE OF STUDY
METHODOLOGY AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY4

Table: TOTAL GLOBAL MARKET SIZE AND FORECAST FOR CHF PHARMACEUTICALS, THROUGH 2016
Figure GLOBAL SUMMARY FIGURE : TOTAL GLOBAL MARKET SIZE AND FORECAST FOR CHF PHARMACEUTICALS, 2010–2016

Chapter- 3: OVERVIEW40

ETIOLOGY
COMPENSATION
CLINICAL PRESENTATION OF CHF
DEMOGRAPHICS
TREATMENTS
PRODUCTS
RESEARCH AND DEVELOPMENT

Chapter- 4: THE GLOBAL MARKET12

GROWTH BY GEOGRAPHIC REGION
GROWTH BY DRUG CLASS
COMPETITIVE ANALYSIS
Table: GLOBAL CHF PHARMACEUTICAL MARKET BY COMPANY, 2011
Figure: GLOBAL CHF PHARMACEUTICAL MARKET SHARES BY COMPANY, 2011
Table: GLOBAL CHF MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE

Chapter- 5: THE AMERICAS MARKET26

REGIONAL MARKETS
CHF POPULATION
REGIONAL DEMOGRAPHICS
AMERICAS CHF MARKET FORECAST
Table: AMERICAS CHF PHARMACEUTICAL MARKET BY GEOGRAPHIC REGION, THROUGH 2016
Figure: AMERICAS CHF MARKET BY GEOGRAPHIC REGION, 2011
Table: AMERICAS CHF MARKET BY DRUG TYPE, THROUGH 2016
Table: AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011
Figure: AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011
Table: AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016
Figure: AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016
Table: U.S. CHF MARKET BY DRUG TYPE, THROUGH 2016
Table: CANADIAN CHF MARKET BY DRUG TYPE, THROUGH 2016
Table: LATIN AMERICAN/SOUTH AMERICAN CHF MARKET BY DRUG TYPE, THROUGH 2016

Chapter- 6: COMPANY PROFILES31

ABBOTT LABORATORIES
ARCA BIOPHARMA
ASTRAZENECA
AUROBINDO PHARMA
BAYER AG
BIOHEART, INC.
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB CO.
CARDIOKINE, INC.
DR. REDDY’S LABORATORIES, LTD.
FOREST LABORATORIES, INC.
GLAXOSMITHKLINE
MERCK
MITSUBISHI TANABE PHARMA CORP.
MYLAN, INC.
NEUROCRINE BIOSCIENCES
NOVARTIS
PFIZER, INC.
SANOFI-AVENTIS, INC.
SERVIER
SHIONOGI & CO., LTD.
TAKEDA PHARMACEUTICALS CO., LTD.
TEVA

Chapter- 7: APPENDIX: DIRECTORY OF COMPANIES17

List of Tables

Summary Table : TOTAL GLOBAL MARKET SIZE AND FORECAST FOR CHF PHARMACEUTICALS, THROUGH 2016
Table 1 : TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHIC REGION, 2000–2050
Table 2 : SELECTED ACE INHIBITORS AVAILABLE FOR THE TREATMENT OF CHF
Table 3 : SELECTED ANGIOTENSIN II RECEPTOR BLOCKERS AVAILABLE FOR THE TREATMENT OF CHF
Table 4 : SELECTED BETA-ADRENERGIC RECEPTOR BLOCKING AGENTS AVAILABLE FOR THE TREATMENT OF CHF
Table 5 : SELECTED DIURETIC AGENTS AVAILABLE FOR TREATMENT OF CHF
Table 6 : SELECTED POSITIVE INOTROPIC DRUGS AVAILABLE FOR THE TREATMENT OF CHF
Table 7 : SELECTED VASODILATORS AVAILABLE FOR THE TREATMENT OF CHF
Table 8 : PRODUCTS IN DEVELOPMENT TO TREAT CHF
Table 9 : GLOBAL MARKET FORECAST FOR CHF PHARMACEUTICALS BY REGION, THROUGH 2016
Table 10 : GLOBAL MARKET SHARES OF CHF PHARMACEUTICAL REVENUES BY REGION, 2011
Table 11 : GLOBAL CHF MARKET BY DRUG TYPE, THROUGH 2016
Table 12 : GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2011
Table 13 : Global CHF Market shares by Drug Type, 2016
Table 14 : GLOBAL CHF PHARMACEUTICAL MARKET BY COMPANY, 2011
Table 15 : GLOBAL CHF MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE
Table 16 : CHF POPULATION IN THE AMERICAS BY COUNTRY, 2011
Table 17 : U.S.’ OLDER POPULATION BY AGE GROUP & CENSUS YEAR, 2000–2050
Table 18 : CANADA’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 19 : BRAZIL’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 20 : MEXICO’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2010
Table 21 : VENEZUELA’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 22 : ARGENTINA’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 23 : PERU’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 24 : CHILE’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 25 : COLOMBIA’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 26 : CUBA’S OLDER POPULATION BY AGE GROUP AND CENSUS YEAR, 2000–2050
Table 27 : AMERICAS CHF PHARMACEUTICAL MARKET BY GEOGRAPHIC REGION, THROUGH 2016
Table 28 : AMERICAS CHF MARKET BY DRUG TYPE, THROUGH 2016
Table 29 : AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011
Table 30 : AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016
Table 31 : U.S. CHF MARKET BY DRUG TYPE, THROUGH 2016
Table 32 : CANADIAN CHF MARKET BY DRUG TYPE, THROUGH 2016
Table 33 : LATIN AMERICAN/SOUTH AMERICAN CHF MARKET BY DRUG TYPE, THROUGH 2016

List of Figures

Summary Figure : TOTAL GLOBAL MARKET SIZE AND FORECAST FOR CHF PHARMACEUTICALS, 2010–2016
Figure 1 : TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHIC REGION, 2000–2050
Figure 2 : GLOBAL MARKET FORECAST FOR CHF PHARMACEUTICALS BY REGION, 2010–2016
Figure 3 : GLOBAL MARKET SHARES OF CHF PHARMACEUTICAL REVENUES BY REGION, 2011
Figure 4 : GLOBAL CHF MARKET BY DRUG TYPE, 2010-2016
Figure 5 : GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2011
Figure 6 : GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2016
Figure 7 : GLOBAL CHF PHARMACEUTICAL MARKET SHARES BY COMPANY, 2011
Figure 8 : AMERICAS CHF MARKET BY GEOGRAPHIC REGION, 2011
Figure 9 : AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011
Figure 10 : AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016